Evidence map›Paper›PMID 41772104›Full record

ArticleScientific reports2026

Multistep loss of catalytic and ligand binding abilities of hexameric purine nucleoside phosphorylase.

Marta Narczyk, Agnieszka Bzowska

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marta NarczykDivision of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, Pasteura 5, 02-093, Warsaw, Poland. Marta.Narczyk@fuw.edu.pl.
Agnieszka BzowskaDivision of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, Pasteura 5, 02-093, Warsaw, Poland. Agnieszka.Bzowska@fuw.edu.pl.

Funding

National Science Centre of Poland N N301 044939, 2015/18/M/NZ1/00776Polish Ministry of Science and Higher Education BST - 163500/BF, BST - 173300/BF task 34, BST-0180100-03/BF task 22, 501-D111-01-1110105 (PP/BF)University of Warsaw IDUB PSP-501-D111-20-0004316
6 · The paper itself

Abstract

It is commonly believed that enzymatic catalysis is such a complex process, that even a small change in any physicochemical property of the enzyme results in a complete loss of the catalytic and ligand-binding capacity of the molecule. Therefore, when the enzyme sample is not fully active, but is electrophoretically pure, the inactive fraction is often considered equal to the non-binding fraction, and constants characterizing ligand binding by such an enzyme and ligand-induced inhibition are determined under this assumption. Here, we present an enzyme, hexameric purine nucleoside phosphorylase, whose gradual loss of a catalytic activity towards natural substrates does not correlate with the loss of the ability to bind ligands, substrates, and inhibitors. The values of dissociation constants characterizing ligand binding depend on the specific activity of the enzyme used in the experiment. Furthermore, there is a stable state of the enzyme, in which it is no longer able to catalyse reaction with natural substrates, but can still catalyse the same reaction if a substrate resembling the transition state is used. The active site conformations of individual subunits in the X-ray structure of this hexameric molecule reflect the presence of intermediate states observed in the enzyme activity decline profiles.

Indexed as

AllosteryBinding fractionCatalytic activityDissociation constantsIncompetent fractionPurine nucleoside phosphorylase

Identifiers

PMID41772104
PMCPMC13057136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.